The Role of AGE/RAGE Signaling in Diabetes-Mediated Vascular Calcification

Journal of Diabetes Research

Volumn 2016, Issue , 2016, Pages

  Kay, Amber M ^a   Simpson, C Lashan ^b   Stewart, James A ^a  

^a MISSISSIPPI STATE UNIVERSITY   (United States)

^b MISSISSIPPI STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; COPPER ZINC SUPEROXIDE DISMUTASE; FETUIN A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE C; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; TRANSFORMING GROWTH FACTOR BETA; NOX1 PROTEIN, HUMAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SOD1 PROTEIN, HUMAN;

BLOOD VESSEL CALCIFICATION; DISEASE SEVERITY; HUMAN; HYPERGLYCEMIA; INNATE IMMUNITY; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOBLAST; OXIDATIVE STRESS; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; COMPLICATION; MAPK SIGNALING; METABOLISM;

ALPHA-2-HS-GLYCOPROTEIN; DIABETES MELLITUS, TYPE 2; GLYCATION END PRODUCTS, ADVANCED; HUMANS; MAP KINASE SIGNALING SYSTEM; NADPH OXIDASE 1; NADPH OXIDASES; NF-KAPPA B; OXIDATIVE STRESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE C; RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS; SIGNAL TRANSDUCTION; SUPEROXIDE DISMUTASE-1; TRANSFORMING GROWTH FACTOR BETA; VASCULAR CALCIFICATION;

EID: 84982113299     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2016/6809703     Document Type: Review

References (70)

1. National Center for Chronic Disease Prevention and Health Promotion, National Diabetes Statistics Report, 2014, 2014.
2. D. Mozaffarian, E. J. Benjamin, A. S. Go et al., "Heart disease and stroke statistics-2016 update: a report from the American Heart Association, " Circulation, vol. 133, no. 4, pp. e38-e60, 2016.
3. R. C. Johnson, J. A. Leopold, and J. Loscalzo, "Vascular calcification: pathobiological mechanisms and clinical implications, " Circulation Research, vol. 99, no. 10, pp. 1044-1059, 2006.
4. F. Palumbo, C. Bianchi, R. Miccoli, and S. Del Prato, "Hyperglycaemia and cardiovascular risk, " Acta Diabetologica, vol. 40, supplement 2, pp. S362-S369, 2003.
5. S. Lehto, L. Niskanen, M. Suhonen, T. Rönnemaa, and M. Laakso, "Medial artery calcification: a neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 16, no. 8, pp. 978-983, 1996.
6. C. M. Giachelli, "Vascular calcification mechanisms, " Journal of the American Society of Nephrology, vol. 15, no. 12, pp. 2959-2964, 2004.
7. M. Wu, C. Rementer, and C. M. Giachelli, "Vascular calcification: an update on mechanisms and challenges in treatment, " Calcified Tissue International, vol. 93, no. 4, pp. 365-373, 2013.
8. L. L. Demer and Y. Tintut, "Vascular calcification: pathobiology of a multifaceted disease, " Circulation, vol. 117, no. 22, pp. 2938-2948, 2008.
9. T. Komori, H. Yagi, S. Nomura et al., "Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts, " Cell, vol. 89, no. 5, pp. 755-764, 1997.
10. K. A. Hruska, S. Mathew, and G. Saab, "Bone morphogenetic proteins in vascular calcification, " Circulation Research, vol. 97, no. 2, pp. 105-114, 2005.
11. K.-S. Lee, S.-H. Hong, and S.-C. Bae, "Both the Smad and p38 MAPK pathways play a crucial role in Runx2 expression following induction by transforming growth factor-and bone morphogenetic protein, " Oncogene, vol. 21, no. 47, pp. 7156-7163, 2002.
12. S. A. Steitz, M. Y. Speer, G. Curinga et al., "Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers, " Circulation Research, vol. 89, no. 12, pp. 1147-1154, 2001.
13. M. Weinreb, D. Shinar, and G. A. Rodan, "Different pattern of alkaline phosphatase, osteopontin, and osteocalcin expression in developing rat bone visualized by in situ hybridization, " Journal of Bone and Mineral Research, vol. 5, no. 8, pp. 831-842, 1990.
14. K. Ibaraki, J. D. Termine, S. W. Whitson, and M. F. Young, "Bone matrix mRNA expression in differentiating fetal bovine osteoblasts, " Journal of Bone and Mineral Research, vol. 7, no. 7, pp. 743-754, 1992.
15. G. K. Hunter and H. A. Goldberg, "Nucleation of hydroxyapatite by bone sialoprotein, " Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 18, pp. 8562-8565, 1993.
16. H. Orimo, "The mechanism of mineralization and the role of alkaline phosphatase in health and disease, " Journal of Nippon Medical School, vol. 77, no. 1, pp. 4-12, 2010.
17. B. Ganss, R. H. Kim, and J. Sodek, "Bone sialoprotein, " Critical Reviews in Oral Biology and Medicine, vol. 10, no. 1, pp. 79-98, 1999.
18. Y. Yang, Q. Cui, and N. Sahai, "How does bone sialoprotein promote the nucleation of hydroxyapatiteamolecular dynamics study using model peptides of different conformations, " Langmuir, vol. 26, no. 12, pp. 9848-9859, 2010.
19. J. Sodek, B. Ganss, and M. D. McKee, "Osteopontin, " Critical Reviews inOral Biology andMedicine, vol. 11, no. 3, pp. 279-303, 2000.
20. S. L. Booth, A. Centi, S. R. Smith, and C. Gundberg, "The role of osteocalcin in human glucose metabolism: marker or mediator" Nature Reviews Endocrinology, vol. 9, no. 1, pp. 43-55, 2013.
21. N. X. Chen, D. Duan, K. D. O'Neill, and S. M. Moe, "High glucose increases the expression of Cbfa1 and BMP-2 andenhances the calcification of vascular smooth muscle cells, " Nephrology Dialysis Transplantation, vol. 21, no. 12, pp. 3435-3442, 2006.
22. D. Koya and G. L. King, "Protein kinase C activation and the development of diabetic complications, " Diabetes, vol. 47, no. 6, pp. 859-866, 1998.
23. A. K. Srivastava, "High glucose-induced activation of protein kinase signaling pathways in vascular smooth muscle cells: a potential role in the pathogenesis of vascular dysfunction in diabetes (review), " International Journal of Molecular Medicine, vol. 9, no. 1, pp. 85-89, 2002.
24. N. X. Chen, D. Duan, K. D. O'Neill et al., "The mechanisms of uremic serum-induced expression of bone matrix proteins in bovine vascular smoothmuscle cells, " Kidney International, vol. 70, no. 6, pp. 1046-1053, 2006.
25. S. Mori, M. Takemoto, K. Yokote, S. Asaumi, and Y. Saito, "Hyperglycemia-induced alteration of vascular smooth muscle phenotype, " Journal of Diabetes and Its Complications, vol. 16, no. 1, pp. 65-68, 2002.
26. M. Takemoto, K. Yokote, M. Nishimura et al., "Enhanced expression of osteopontin in human diabetic artery and analysis of its functional role in accelerated atherogenesis, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 3, pp. 624-628, 2000.
27. M. Takemoto, K. Yokote, M. Yamazaki et al., "Enhanced expression of osteopontin by high glucose in cultured rat aortic smooth muscle cells, " Biochemical and Biophysical Research Communications, vol. 258, no. 3, pp. 722-726, 1999.
28. S. Soman, R. Raju, V. K. Sandhya et al., "A multicellular signal transduction network of AGE/RAGE signaling, " Journal of Cell Communication and Signaling, vol. 7, no. 1, pp. 19-23, 2013.
29. A. W. Stitt, Y. M. Li, T. A. Gardiner, R. Bucala, D. B. Archer, and H. Vlassara, "Advanced glycation end products (AGEs) colocalize withAGE receptors in the retinal vasculature of diabetic and of AGE-infused rats, " American Journal of Pathology, vol. 150, no. 2, pp. 523-531, 1997.
30. A. W. Stitt, J. E. Moore, J. A. Sharkey et al., "Advanced glycation end products in vitreous: structural and functional implications for diabetic vitreopathy, " Investigative Ophthalmology & Visual Science, vol. 39, no. 13, pp. 2517-2523, 1998.
31. F. Giacco and M. Brownlee, "Oxidative stress and diabetic complications, " Circulation Research, vol. 107, no. 9, pp. 1058-1070, 2010.
32. R. Singh, A. Barden, T. Mori, and L. Beilin, "Advanced glycation end-products: a review, " Diabetologia, vol. 44, no. 2, pp. 129-146, 2001.
33. A. Goldin, J. A. Beckman, A. M. Schmidt, and M. A. Creager, "Advanced glycation end products: sparking the development of diabetic vascular injury, " Circulation, vol. 114, no. 6, pp. 597-605, 2006.
34. M. Sakaguchi, H. Murata, K.-I. Yamamoto et al., "TIRAP, an adaptor protein for TLR2/4, transduces a signal from RAGE phosphorylated upon ligand binding, " PLoS ONE, vol. 6, no. 8, article e23132, 2011.
35. P. Geraldes and G. L. King, "Activation of protein kinase C isoforms and its impact on diabetic complications, " Circulation Research, vol. 106, no. 8, pp. 1319-1331, 2010.
36. T. Suga, T. Iso, T. Shimizu et al., "Activation of receptor for advanced glycation end products induces osteogenic differentiation of vascular smoothmuscle cells, " Journal of Atherosclerosis andThrombosis, vol. 18, no. 8, pp. 670-683, 2011.
37. T. Tanikawa, Y. Okada, R. Tanikawa, and Y. Tanaka, "Advanced glycation end products induce calcification of vascular smooth muscle cells through rage/p38 MAPK, " Journal of Vascular Research, vol. 46, no. 6, pp. 572-580, 2009.
38. Y. Hu, E. Chan, S. X. Wang, and B. Li, "Activation of p38 mitogen-activated protein kinase is required for osteoblast differentiation, " Endocrinology, vol. 144, no. 5, pp. 2068-2074, 2003.
39. X. Ren, H. Shao, Q. Wei, Z. Sun, and N. Liu, "Advancedglycation end-products enhance calcification in vascular smooth muscle cells, " Journal of International Medical Research, vol. 37, no. 3, pp. 847-854, 2009.
40. S. M. Moe, D. Duan, B. P. Doehle, K. D. O'Neill, and N. X. Chen, "Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels, " Kidney International, vol. 63, no. 3, pp. 1003-1011, 2003.
41. Q. Wei, X. Ren, Y. Jiang, H. Jin, N. Liu, and J. Li, "Advanced glycation end products accelerate rat vascular calcification through RAGE/oxidative stress, " BMC Cardiovascular Disorders, vol. 13, article 13, 2013.
42. N. Stefan, A. Fritsche, C. Weikert et al., "Plasma fetuin-A levels and the risk of type 2 diabetes, " Diabetes, vol. 57, no. 10, pp. 2762-2767, 2008.
43. M. Singh, P. K. Sharma, V. K. Garg, S. C. Mondal, A. K. Singh, and N. Kumar, "Role of fetuin-A in atherosclerosis associated with diabetic patients, " Journal of Pharmacy and Pharmacology, vol. 64, no. 12, pp. 1703-1708, 2012.
44. A. Song, M. Xu, Y. Bi et al., "Serum fetuin-A associates with type 2 diabetes and insulin resistance in Chinese adults, " PLoS ONE, vol. 6, no. 4, Article ID e19228, 2011.
45. N. J. Paloian and C. M. Giachelli, "A current understanding of vascular calcification in CKD, " American Journal of Physiology-Renal Physiology, vol. 307, no. 8, pp. F891-F900, 2014.
46. I. Hameed, S. R. Masoodi, S. A. Mir, M. Nabi, K. Ghazanfar, and B. A. Ganai, "Type 2 diabetes mellitus: from a metabolic disorder to an inflammatory condition, " World Journal of Diabetes, vol. 6, no. 4, pp. 598-612, 2015.
47. D. Pal, S. Dasgupta, R. Kundu et al., "Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance, " Nature Medicine, vol. 18, no. 8, pp. 1279-1285, 2012.
48. H. Wang and A. E. Sama, "Anti-inflammatory role of fetuin-A in injury and infection, " CurrentMolecularMedicine, vol. 12, no. 5, pp. 625-633, 2012.
49. R. Kokkola, A. Andersson, G. Mullins et al., "RAGE is themajor receptor for the proinflammatory activity of HMGB1 in rodent macrophages, " Scandinavian Journal of Immunology, vol. 61, no. 1, pp. 1-9, 2005.
50. T. Schinke, C. Amendt, A. Trindl, O. Pöschke, W. Müller-Esterl, and W. Jahnen-Dechent, "The serum protein 2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. Apossible role in mineralization and calcium homeostasis, "The Journal of Biological Chemistry, vol. 271, no. 34, pp. 20789-20796, 1996.
51. K. Janda, M. Krzanowski, M. Gajda et al., "Vascular effects of advanced glycation end-products: content of immunohistochemically detected AGEs in radial artery samples as a predictor for arterial calcification and cardiovascular risk in asymptomatic patients with chronic kidney disease, " Disease Markers, vol. 2015, Article ID 153978, 9 pages, 2015.
52. M. Ketteler, P. Bongartz, R. Westenfeld et al., "Association of low fetuin-A (AHSG) concentrations in serum with cardiovascularmortality in patients on dialysis: a cross-sectional study, " The Lancet, vol. 361, no. 9360, pp. 827-833, 2003.
53. A. M. El-Shehaby, A. Zakaria, M. El-Khatib, and N. Mostafa, "Association of fetuin-A and cardiac calcification and inflammation levels in hemodialysis patients, " Scandinavian Journal of Clinical and Laboratory Investigation, vol. 70, no. 8, pp. 575-582, 2010.
54. C. Schäfer, A. Heiss, A. Schwarz et al., "The serum protein 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification, "The Journal of Clinical Investigation, vol. 112, no. 3, pp. 357-366, 2003.
55. A. Heiss, A. DuChesne, B. Denecke et al., "Structural basis of calcification inhibition by 2-HS glycoprotein/fetuin-A: formation of colloidal calciprotein particles, " Journal of Biological Chemistry, vol. 278, no. 15, pp. 13333-13341, 2003.
56. E. S. Vasquez, J. L. Cunningham, J. B. McMahan, C. L. Simpson, and K. B. Walters, "Fetuin-A adsorption and stabilization of calcium carbonate nanoparticles in a simulated body fluid, " Journal of Materials Chemistry B, vol. 3, no. 31, pp. 6411-6419, 2015.
57. J. L. Reynolds, J. N. Skepper, R. McNair et al., "Multifunctional roles for serumprotein fetuin-Ain inhibition of human vascular smooth muscle cell calcification, " Journal of the American Society of Nephrology, vol. 16, no. 10, pp. 2920-2930, 2005.
58. J. L. Reynolds, A. J. Joannides, J. N. Skepper et al., "Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calciumand phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD, " Journal of the American Society of Nephrology, vol. 15, no. 11, pp. 2857-2867, 2004.
59. D. Proudfoot, J. N. Skepper, L. Hegyi, M. R. Bennett, C. M. Shanahan, and P. L. Weissberg, "Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies, " Circulation Research, vol. 87, no. 11, pp. 1055-1062, 2000.
60. M. El-Abbadi and C. M. Giachelli, "Mechanisms of vascular calcification, " Advances in Chronic Kidney Disease, vol. 14, no. 1, pp. 54-66, 2007.
61. S. M. Moe, M. Reslerova, M. Ketteler et al., "Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD), " Kidney International, vol. 67, no. 6, pp. 2295-2304, 2005.
62. G. Daffu, C. H. del Pozo, K. M. O'Shea, R. Ananthakrishnan, R. Ramasamy, and A. M. Schmidt, "Radical roles for RAGE in the pathogenesis of oxidative stress in cardiovascular diseases and beyond, " International Journal ofMolecular Sciences, vol. 14, no. 10, pp. 19891-19910, 2013.
63. K. R. Hutchinson, C. K. Lord, T. A. West, and J. A. Stewart Jr., "Cardiac fibroblast-dependent extracellular matrix accumulation is associated with diastolic stiffness in type 2 diabetes, " PLoS ONE, vol. 8, no. 8, Article ID e72080, 2013.
64. J. L. Rains and S. K. Jain, "Oxidative stress, insulin signaling, and diabetes, " Free Radical Biology and Medicine, vol. 50, no. 5, pp. 567-575, 2011.
65. M. R. Brodeur, C. Bouvet, S. Bouchard et al., "Reduction of advanced-glycation end products levels and inhibition of RAGE signaling decreases rat vascular calcification induced by diabetes, " PLoS ONE, vol. 9, no. 1, Article ID e85922, 2014.
66. J. H. Li, X. R. Huang, H.-J. Zhu et al., "Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease, " The FASEB Journal, vol. 18, no. 1, pp. 176-178, 2004.
67. C. M. Zimmerman and R. W. Padgett, "Transforming growth factor signaling mediators and modulators, " Gene, vol. 249, no. 1-2, pp. 17-30, 2000.
68. R.-M. Liu and K. A. Gaston Pravia, "Oxidative stress and glutathione in TGF-mediated fibrogenesis, " Free Radical Biology and Medicine, vol. 48, no. 1, pp. 1-15, 2010.
69. E. Simard, T. Söllradl, J.-S. Maltais, J. Boucher, P. D'Orléans-Juste, and M. Grandbois, "Receptor for advanced glycation endproducts signaling interferes with the vascular smooth muscle cell contractile phenotype and function, " PLoS ONE, vol. 10, no. 8, Article ID e0128881, 2015.
70. Y. Peng, J.-M. Kim, H.-S. Park et al., "AGE-RAGE signal generates a specific NF-B RelA 'barcode' that directs collagen I expression, " Scientific Reports, vol. 6, Article ID 18822, 2016.